ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1479

Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample 

Faria Sami and Shilpa Arora, John H. Stroger, Jr. Hospital of Cook County, Chicago, IL

Meeting: ACR Convergence 2022

Keywords: neurology, Systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 13, 2022

Title: SLE – Diagnosis, Manifestations, and Outcomes Poster II: Manifestations

Session Type: Poster Session C

Session Time: 1:00PM-3:00PM

Background/Purpose: Neuromyelitis Optica (NMO), also known as Devic’s disease, is a rare inflammatory demyelinating disorder causing myelitis and optic neuritis. While there have been reports of autoimmune diseases associated with NMO, especially Systemic Lupus erythematosus (SLE), a formal association between the two is not established. We aimed to investigate the occurrence of NMO in SLE patients and study the characteristics and outcomes of NMO and SLE hospitalizations utilizing the national inpatient sample (NIS) database.

Methods: The NIS database from 2016 to 2019 was used to extract data. Hospitalizations with the principal diagnosis of NMO with a secondary diagnosis of SLE were searched. Only adult patients above the age of 18 years were included. We studied and compared the characteristics and outcomes of SLE hospitalizations with and without NMO and performed regression analyses for statistical analysis. We also calculated the risk of NMO in SLE amongst all adult hospitalizations.

Results: There was a total of 6,965 adult hospitalizations with the principal discharge diagnosis of NMO. Among all SLE hospitalizations, 415 (0.05%) had the principal diagnosis of NMO. Patient characteristics and demographics of SLE patients with and without NMO are depicted in Table 1. SLE patients with NMO were younger in comparison to those without NMO (mean age 44.20 vs 52.51, P value < 0.001) and were more likely to be of African American (55.42% vs 30.21%, P value < 0.001) and Asian ethnicity (6.02% vs 2.36%, P value 0.04). These patients were more likely to have Medicaid or private insurance and were more often admitted to large bed size hospitals. None of the patients with SLE and NMO died. SLE and NMO patients had a longer length of stay in comparison to SLE patients without NMO (9.94 vs 5.45 days, P value < 0.001) as well as higher total charges (Table 2). The odds of NMO in SLE amongst all adult hospitalizations was 10.58 (P-value < 0.001).

Conclusion: SLE patients had a 10-fold higher risk of being hospitalized with NMO in comparison to the general population. SLE patients with NMO were more likely to be younger and of African American and Asian ethnicity. NMO did not impact mortality in SLE hospitalizations but increased the health care economic burden.

Supporting image 1

Table 1: Demographics and characteristics of SLE hospitalizations with and without NMO

Supporting image 2

Table 2: Outcomes of SLE hospitalizations with and without NMO


Disclosures: F. Sami, None; S. Arora, None.

To cite this abstract in AMA style:

Sami F, Arora S. Association of Neuromyelitis Optica and Systemic Lupus Erythematosus: Analysis of National Inpatient Sample  [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/association-of-neuromyelitis-optica-and-systemic-lupus-erythematosus-analysis-of-national-inpatient-sample/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/association-of-neuromyelitis-optica-and-systemic-lupus-erythematosus-analysis-of-national-inpatient-sample/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology